273 related articles for article (PubMed ID: 15270667)
1. Neoadjuvant chemotherapy in ovarian cancer.
Park TW; Kuhn WC
Expert Rev Anticancer Ther; 2004 Aug; 4(4):639-47. PubMed ID: 15270667
[TBL] [Abstract][Full Text] [Related]
2. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
Vergote I; Amant F; Kristensen G; Ehlen T; Reed NS; Casado A
Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
[TBL] [Abstract][Full Text] [Related]
3. [Neoadjuvant chemotherapy for advanced epithelial ovarian cancer].
Hatae M; Onishi Y; Nakamura T; Yamamoto H; Kusumoto M; Matsui T; Mihara K; Taniguchi H
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1833-7. PubMed ID: 11729475
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.
Vergote I; De Wever I; Tjalma W; Van Gramberen M; Decloedt J; van Dam P
Gynecol Oncol; 1998 Dec; 71(3):431-6. PubMed ID: 9887245
[TBL] [Abstract][Full Text] [Related]
5. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer.
Huober J; Meyer A; Wagner U; Wallwiener D
J Cancer Res Clin Oncol; 2002 Mar; 128(3):153-60. PubMed ID: 11935302
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study.
Ansquer Y; Leblanc E; Clough K; Morice P; Dauplat J; Mathevet P; Lhommé C; Scherer C; Tigaud JD; Benchaib M; Fourme E; Castaigne D; Querleu D; Dargent D
Cancer; 2001 Jun; 91(12):2329-34. PubMed ID: 11413522
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.
Vergote IB; De Wever I; Decloedt J; Tjalma W; Van Gramberen M; van Dam P
Semin Oncol; 2000 Jun; 27(3 Suppl 7):31-6. PubMed ID: 10952124
[TBL] [Abstract][Full Text] [Related]
9. [Neoadjuvant chemotherapy and ovarian cancer].
Ray-Coquard I; Saba C; Bachelot T; Méeus P; Mignotte H; Blondet R; Treilleux I; Peix M; Guastalla JP
Bull Cancer; 2006 Jul; 93(7):669-76. PubMed ID: 16873075
[TBL] [Abstract][Full Text] [Related]
10. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer.
Morice P; Dubernard G; Rey A; Atallah D; Pautier P; Pomel C; Lhommé C; Duvillard P; Castaigne D
J Am Coll Surg; 2003 Dec; 197(6):955-63. PubMed ID: 14644284
[TBL] [Abstract][Full Text] [Related]
11. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.
Bristow RE; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1070-6. PubMed ID: 16875720
[TBL] [Abstract][Full Text] [Related]
12. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.
Lee SJ; Kim BG; Lee JW; Park CS; Lee JH; Bae DS
J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534
[TBL] [Abstract][Full Text] [Related]
13. The position of neoadjuvant chemotherapy within the treatment of ovarian cancer.
Van Gorp T; Amant F; Neven P; Berteloot P; Leunen K; Vergote I
Minerva Ginecol; 2006 Oct; 58(5):393-403. PubMed ID: 17006426
[TBL] [Abstract][Full Text] [Related]
14. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer.
Lim MC; Song YJ; Seo SS; Yoo CW; Kang S; Park SY
Onkologie; 2010; 33(6):324-30. PubMed ID: 20523098
[TBL] [Abstract][Full Text] [Related]
15. [Ovarian cancer].
Onda T
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1735-9. PubMed ID: 18030006
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas.
Matsuo K; Eno ML; Im DD; Rosenshein NB
Arch Gynecol Obstet; 2010 Feb; 281(2):325-8. PubMed ID: 19455347
[TBL] [Abstract][Full Text] [Related]
17. [Neoadjuvant chemotherapy in the treatment of ovarian cancer].
Lehoczky O
Orv Hetil; 2005 Sep; 146(38):1951-5. PubMed ID: 16238247
[TBL] [Abstract][Full Text] [Related]
18. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Hopkins L; Faught W; Fung-Kee-Fung M
Gynecol Oncol; 2007 Jun; 105(3):712-5. PubMed ID: 17400284
[TBL] [Abstract][Full Text] [Related]
19. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
[TBL] [Abstract][Full Text] [Related]
20. [The role of surgery for advanced epithelial ovarian cancer].
Hatae M; Onishi Y; Nakamura T; Wada T
Gan To Kagaku Ryoho; 1998 Jan; 25(2):201-7. PubMed ID: 9474929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
